Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.03T
Market cap1.03T
Price-Earnings ratio
38.33
Price-Earnings ratio38.33
Dividend yield
0.59%
Dividend yield0.59%
Average volume
2.91M
Average volume2.91M
High today
$1,092.39
High today$1,092.39
Low today
$1,065.48
Low today$1,065.48
Open price
$1,070.75
Open price$1,070.75
Volume
641.93K
Volume641.93K
52 Week high
$1,133.95
52 Week high$1,133.95
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

Eli Lilly(LLY) stock is priced at $1,091.63, giving the company a market capitalization of 1.03T. It carries a P/E multiple of 38.33 and pays a dividend yield of 58.5%.

On 2026-05-27, Eli Lilly(LLY) stock traded between a low of $1,065.48 and a high of $1,092.39. Shares are currently priced at $1,091.63, which is +2.5% above the low and -0.1% below the high.

The Eli Lilly(LLY)'s current trading volume is 641.93K, compared to an average daily volume of 2.91M.

In the last year, Eli Lilly(LLY) shares hit a 52-week high of $1,133.95 and a 52-week low of $623.78.

In the last year, Eli Lilly(LLY) shares hit a 52-week high of $1,133.95 and a 52-week low of $623.78.

LLY News

Simply Wall St 6h
Eli Lilly’s Vaccine Push Reshapes Growth Story Beyond Obesity And Diabetes

Eli Lilly (NYSE:LLY) is spending nearly $4 billion to acquire three vaccine companies: Curevo, LimmaTech Biologics, and Vaccine Company. The deals expand Lilly...

Eli Lilly’s Vaccine Push Reshapes Growth Story Beyond Obesity And Diabetes
Zacks 7h
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novo Nordisk and Bayer

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All...

Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novo Nordisk and Bayer
Nasdaq 16h
Is Eli Lilly Stock an Undervalued Stock to Buy?

The pharma company is booming due to innovative treatments. Will AI create the world's first trillionaire? Our team just released a report on the one little-kn...

Is Eli Lilly Stock an Undervalued Stock to Buy?

Analyst ratings

85%

of 33 ratings
Buy
84.8%
Hold
9.1%
Sell
6.1%

More LLY News

Cheddar 20h
Eli Lilly Spends Nearly Four Billion Dollars on Vaccine Expansion

Eli Lilly Spends Nearly Four Billion Dollars on Vaccine Expansion Pharmaceutical giant Eli Lilly announced plans to acquire three vaccine developers in deals w...

Eli Lilly Spends Nearly Four Billion Dollars on Vaccine Expansion
TipRanks 22h
Eli Lilly Stock Climbs Higher on News of $4 Billion Acquisition Spree

Eli Lilly (LLY) stock is rising on news that the company is acquiring multiple vaccine makers for nearly $4 billion in cash. Unlock trusted, data-backed invest...

TipRanks 24h
Morning Movers: Eli Lilly gets boost amid plans for nearly $4B in vaccine deals

Stock futures rose Tuesday as markets reacted to reports of potential progress in U.S.–Iran talks aimed at ending the conflict, with sentiment supported by Pres...

Investor's Business Daily 1d
Eli Lilly Goes On A $3.83 Billion Acquisition Spree. Where's It Pushing Now?

How Eli Lilly's Next-Gen Obesity Drug Is 'Raising The Bar' In Weight Loss 5/21/2026 Patients lost up to 85 pounds in a study of Eli Lilly's next-generation wei...

Eli Lilly Goes On A $3.83 Billion Acquisition Spree. Where's It Pushing Now?
TipRanks 1d
Eli Lilly price target raised to $1,251 from $1,133 at BofA

BofA raised the firm’s price target on Eli Lilly (LLY) to $1,251 from $1,133 and keeps a Buy rating on the shares. The firm expects Lilly’s overall revenue and...

TipRanks 1d
Eli Lilly agrees to buy vaccine makers in deals worth up to $4B, WSJ reports

Eli Lilly (LLY) is expanding into infectious-disease prevention through acquisitions of vaccine developers Curevo, LimmaTech Biologics, and Vaccine Co. in deals...

Benzinga 1d
Chamath Palihapitiya Said This To Eli Lilly's Gene Therapy That Slashes LDL Cholesterol Up To 62%

What Triggered The Reaction On Monday, Lilly reported positive Phase 1b data for VERVE-102, an investigational in vivo base editing medicine designed to permane...

Chamath Palihapitiya Said This To Eli Lilly's Gene Therapy That Slashes LDL Cholesterol Up To 62%

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.